OnCo
technologiesTechnologyPhase 1

Histotripsy as an immune primer

Destroying a tumour mechanically with sound, rather than heat, leaves the debris intact enough for the immune system to learn from it.

Histotripsy liquefies tissue by cavitation without heating, so tumour antigens and danger signals survive in a form that heat coagulation destroys. Preclinical models show abscopal responses and synergy with checkpoint blockade, and the approved liver device provides a clinical platform. Human immune data are early and no randomised combination trial has reported.

Generic schematic · not to scale · placeholder for the surgery front
Patient-side cart · Wristed instrument arms · Target through 8 mm ports

How it works

Microsecond ultrasound pulses generate a cavitation bubble cloud that mechanically fractionates tissue at the focus, releasing intact antigens and danger signals that prime an immune response.

Strengths
  • Non-thermal, so antigens survive
  • Non-invasive and repeatable
  • Approved hardware already installed in hospitals
Limitations
  • Immune effect unproven in humans
  • Acoustic window limits which tumours can be treated
  • No randomised combination data

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Histotripsy as an immune primer" OR ABSTRACT:"Histotripsy as an immune primer") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Histotripsy as an immune primer, not a curated reading list.

Connected

11top

Pages like this

not linked directly; found by shared links